Stocks
Single names, sectors, valuations and the trades behind the tape, explained in plain language.
Atkore jumps on $3.8B Prysmian buyout; Lindblad, Marcus also gain
Atkore jumped after agreeing to a $3.8 billion all-cash takeover by Prysmian. Lindblad Expeditions raised its 2026 revenue outlook, and Marc
Movie stocks shine as Marriott drags on mixed consumer day
Movie theater stocks popped on record box office results, while Marriott slid after a soft quarter. The split shows why 'the consumer' isn't
AstraZeneca and Bristol Myers Squibb in talks for record pharma merger
AstraZeneca and Bristol Myers Squibb are reportedly in talks for a mega-merger that could be the largest in pharma history. Combined, they'd
AbbVie's Next Catalyst: Pipeline Data as Skyrizi Faces Pricing Pressure
RBC Capital Markets says AbbVie's blockbuster drugs Skyrizi and Rinvoq are holding up well, but pricing pressure will persist. The next big
CRH's US infrastructure and data center focus drives Q2 beat, RBC says
CRH's second-quarter results beat expectations, driven by its US infrastructure footprint and data center construction, which offset sluggis
Morgan Stanley cuts Block price target to $90 ahead of Q2 earnings
Morgan Stanley lowered its price target on Block to $90 from $98 ahead of the fintech's Q2 earnings, citing softer expectations for Cash App
TF1 weighs €400M sale of Studio TF1 to fund streaming push
French broadcaster TF1 is weighing a sale of its production and distribution arm, Studio TF1, at a valuation of around €400 million. The pro
Robinhood's second venture fund goes public to open private investing
Robinhood is taking its second venture fund public, pitching shares at $25 to raise up to $200 million for early-stage bets, with a focus on
Latigo and BlossomHill IPOs test biotech's fragile market reopening
Two biotech companies, Latigo Biotherapeutics and BlossomHill Therapeutics, are listing on Nasdaq, testing whether investors are ready to fu
Curium to buy Lantheus in up to $8 billion radiopharma deal
Curium, backed by private equity firm CapVest, will buy Lantheus in a deal valued at up to $8 billion. Shareholders get $102.50 per share in
KKR to Buy Integer Holdings for $5.7 Billion in Cash Deal
KKR will buy Integer Holdings for $127 a share in cash, valuing the medical-device outsourcer at about $5.7 billion. The deal is expected to
Tesla's July Europe sales diverge sharply by country
Tesla's July registrations rose 86% in France and 52% in Denmark, but fell 97% in Norway and dropped sharply in Sweden and Spain. The split